ROQ.LSE

Roquefort Investments PLC

ROQ.LSE, UK

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.

https://www.roquefortplc.com

Stock Price

GBp 0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ROQ.LSE
stock
ROQ.LSE

FTSE 100 Live: London stocks fall as cannabis news hits tobacco giants, US tech slumps Proactive financial news

Read more →
ROQ.LSE
stock
ROQ.LSE

Roquefort Therapeutics shares marked ex-entitlement for unlisted shares Investing.com

Read more →

Showing 2 of 6

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

40.38

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-10.31 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-8.66 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.19

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Roquefort Investments PLC

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-06-30)

Revenue

£ 0

Cost Of Revenue

£ 0

Gross Profit

£ 0

Operating Expenses

£ 0

Operating Income

£ 0

Interest Expense

£ 0

Pretax Income

£ 0

Net Income

£ 0

Income Tax Expense

£ 0

EBITDA

£ 0

Total Other Income Expense Net

£ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

£ 0

Short Term Investments

£ 0

Receivables

£ 0

Inventories

£ 0

Total Current Assets

£ 0

Property Plant Equipment

£ 0

Total Assets

£ 0

Payables

£ 0

Short Term Debt

£ 0

Long Term Debt

£ 0

Total Liabilities

£ 0

Equity

£ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

£ 0

Depreciation

£ 0

Change In Working Capital

£ 0

Cash From Operations

£ 0

Capital Expenditures

£ 0

Cash From Investing

£ 0

Cash From Financing

£ 0

Net Change In Cash

£ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.